Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 2/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3034608 | 0.86 | CCR5 (0.53) | CCR5SIGMAR1KMT2AOPRM1LMNA | |
| SCHEMBL3051138 | 0.83 | CCR5 (0.56) | CCR5SIGMAR1KMT2AMEN1POLB | |
| SCHEMBL3044722 | 0.79 | ALOX5 (0.60) | CCR5SIGMAR1OPRM1LMNAL3MBTL1 | |
| SCHEMBL3035425 | 0.79 | SIGMAR1 (0.63) | CCR5SIGMAR1KMT2AMEN1POLB | |
| SCHEMBL2404816 | 0.78 | CCR5 (0.66) | CCR5SIGMAR1KMT2AMEN1POLB | |
| SCHEMBL30804752 | 0.77 | MCHR1 (0.53) | KMT2AMEN1POLBL3MBTL1 | |
| SCHEMBL30804735 | 0.77 | MCHR1 (0.53) | KMT2AMEN1POLBL3MBTL1 | |
| SCHEMBL3051106 | 0.77 | KDM4E (0.60) | SIGMAR1KMT2APOLBLMNAL3MBTL1 | |
| SCHEMBL3055294 | 0.77 | KMT2A (0.61) | CCR5SIGMAR1KMT2AMEN1POLB | |
| SCHEMBL3046877 | 0.76 | CCR5 (0.54) | CCR5KMT2AMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1434765-B1 | SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING TO HISTAMINE H3-RECEPTOR | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-12-02 | — | — | EP | claimed |
| US-20100222386-A1 | SUBSTITUTED PIPERIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222386-A1 | SUBSTITUTED PIPERIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222386-A1 | SUBSTITUTED PIPERIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-7767695-B2 | Substituted piperidines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767695-B2 | Substituted piperidines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767695-B2 | Substituted piperidines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-03 | — | — | US | disclosed |
| EP-1434765-B1 | SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING TO HISTAMINE H3-RECEPTOR | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222386-A1 | SUBSTITUTED PIPERIDINES | HRH3, HRH4, HRH2 | CCR5 565/4885SIGMAR1 142/4885KMT2A 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.